1 Towards equitable and affordable medicine prices policies in Jordan Interpretation of Jordanian Patent Law and JUSFTA to improve access to medicines.

Slides:



Advertisements
Similar presentations
GATT AND TRIPS.
Advertisements

Refugee Protection Division Navigating the Sea of Change – Refugee Lawyers Group CLE 2013.
Impact of JUSFTA on affordability and availability of medicines from perspective of local generic manufacturers Towards equitable and affordable medicine.
SEM21-02 ETSI Seminar 2010 « Legal Considerations » Erik Jansen, LL.M. ETSI Legal Director Copyright © ETSI All rights reserved. ETSI Seminar Sophia.
Ethical aspects and Patents in Lifescience Peter R. Thomsen Manager Global IP Litigation, Corporate Intellectual Property, Novartis WIPO symposium on IP.
2 Policy Considerations 1. Introduction 2. Policy considerations 3. Practical measures.
INTERNATIONAL TRADEMARK ASSOCIATION INTA GI TRIPS 23.4 Multilateral Register Proposal CLARK W. LACKERT, Chair, INTA GI Committee and Partner, King & Spalding.
WIPO National Seminar on Copyright and Related Rights for Lawyers and Judges Damacus, April 27 and 28, 2005 Policy Considerations and Practical Measures.
Pharma Workshop IV Patent Linkage in the USA Lawrence T. Welch Eli Lilly and Company.
1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
Using FTA Side Letters and Congressional Letters to Authorize Waiver of Data Exclusivity and Linkage Professor Brook K. Baker Northeastern U. School of.
Access to medicines – Barriers relating to intellectual property rights and data exclusivity Julian Cockbain & Sigrid Sterckx Yale conference Human rights.
China on the way to a high-technology country: The legal policy perspective Stefan Luginbuehl Lawyer, International Legal Affairs.
1 Review of Art 39.3 TRIPS – interpretation and controversy Sanya Smith Third World Network 25 August 2006 Bangkok.
Challenges and Opportunities to Utilize TRIPS Flexibilities in Current Ukrainian Legislation: Potential Impact of IP Provisions in the Proposed EU FTA.
EU: Bilateral Agreements of Member States
Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.
A New Pathway for Follow-on Biologics Presented by: Steve Nash May 7, 2010.
The Life Sciences Lawyer’s Guide to PTA and PTE
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA AN OVERVIEW OF PATENT PROTECTION IN ZAMBIA.
SAREE AONGSOMWANG Foundation for Consumers, Thailand.
Patent Related Flexibilities in the Pharmaceutical Field
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
International Max Planck Research School for Competition and Innovation WIPO – Owais Hassan Shaikh IMPRS-CI 2010 Data Exclusivity Provisions.
Data exclusivity, patents and registration of medicines Karin Timmermans TWN Regional Workshop Kuala Lumpur on bilateral trade agreements Aug
TRIPS plus FTAs Rohit Malpani Oxfam America. Public health consequences of TRIPS plus FTAs Prospective studies on FTAs with TRIPS plus provisions –US.
The Impact of the TTIP on Europe’s Investment Arbitration Architecture Dr. Roland Kläger10. DAJV Fachgruppentag - 21 March 2014.
Vienna Convention on the Law of Treaties Article 31 1.A treaty shall be interpreted in good faith in accordance with the ordinary meaning to be given to.
The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
O VERVIEW OF P UBLIC H EALTH -R ELATED TRIPS F LEXIBILITIES Sisule F. Musungu, IQsensato (
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Test data protection TRIPS requirements & TRIPS-plus provisions Carlos Correa.
TRIPS+ provisions in FTAs and the implications for access to medicines Sanya Smith Third World Network 27 August 2005.
ADAMS & ADAMS Intellectual Property within the Pharmaceutical Industry Presentation to SAPRAA. 04 September 2009 By : Alexis Apostolidis B.Sc (Chem, Law);
UNCTAD/CD-TFT 1 IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade.
UNCTAD/CD-TFT 1 Basic Features of the Multilateral Systems of Patents and Regulatory Test Data Development Dimensions of Intellectual Property Rights Hanoi.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Regional Dialogue on EPAs, IP and Sustainable Development for ECOWAS Countries Dialogue organised by ICTSD, ENDA Tiers Monde & QUNO Saly (Dakar), Senegal,
Data Protection in compliance with Article 39 of the TRIPS Agreement Draft Amendment to the Drugs Act 1976 Humaira Mufti WIPO National Seminar on Flexibilities.
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
SM © 2012 Patterson Thuente Christensen Pedersen, P.A., some rights reserved - DISCLAIMER: This presentation and any information.
IMPACT OF THE DOHA DECLARATION November 14, 2011 Carlos M. Correa.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
Biotechnology Chemical Pharmaceutical Customer Partnership
Reform(aliz)ing Copyright BCLT, April 18-19, 2013 Three Steps Towards Formalities Prof. Martin Senftleben VU University Amsterdam Bird & Bird, The Hague.
Women’s law and human rights: Introduction to legal theory and methods Ingunn Ikdahl
Top 10 Legal Minefields A University Perspective October 8, 2009 Catherine Shea Associate University Counsel University of Colorado.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Change Orders, Extras and Claims Presented by Geoffrey Cantello, City of Ottawa.
Intellectual Property and Public Policy: Application of Flexibilities in the International IP and Trade system --Limitation and Exceptions for Education.
Substance-over-form as an interpretation canon Chi Chung May 12, 2016.
Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.
Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.
ABA Annual Meeting All Rights Reserved Brief Overview of the Intellectual Property System in China Elizabeth Chien-Hale
Article 4 [Obligations of Applicant] 4.1. As a sole and exclusive owner of the Application, Applicant warrants that.
TRADE SECRETS workshop I © 2009 Prof. Charles Gielen EU-China Workshop on the Protection of Trade Secrets Shanghai June 2009.
Overview of presentation
Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.
Intellectual Property Protection and Access to Medicines
Patent law update.
IP Protection under the WTO
ICJ – Reservations to the Convention on Genocide A.O. (1951)
IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade Agreements.
International Copyright Legal Framework
ICJ – Reservations to the Convention on Genocide A.O. (1951)
Presentation transcript:

1 Towards equitable and affordable medicine prices policies in Jordan Interpretation of Jordanian Patent Law and JUSFTA to improve access to medicines Dead Sea 4-5 December 2007 Presented by: Hiba A. Zarour, Esq. *BSc. Pharmacy, Master of Intellectual Property, Juris Doctor * Admitted in New York and Massachusetts Intellectual Property Counsel

2 What should the Government do to ensure access? Do not close the door on interpreting or even challenging IP laws, this is what courts are for, laws and agreements are not gospel. Listen and give equal credibility to all parties Legislate wisely. Do not provide an overkill, balance rights with exceptions. Insist on flexibilities and make use of them Learn and Consult with other governments who underwent the experience Contact NGOs, WIPO and ask for experts help

3 In Pharmaceuticals the Need for a Balanced Legal System is Essential Rules are important to ensure Intellectual Property protection of the new medicines so they would be created to alleviate human suffering. Limitations on these rules are equally important to have medicines that are readily available and affordable.

4 What is Ever-greening? Ever-greening : is not a formal concept of patent law. It is best understood as a social idea used to refer to the innumerable ways in which a pharmaceutical patent owners utilize the law and related regulatory processes to extend their high rent earning intellectual property privileges particularly over highly profitable blockbuster drugs. We have to interpret agreements in a way to prevent ever-greening. Australia, Canada enacted anti-ever-greening legislation to battle provisions of the FTA that could delay introduction of generics. Thomas A Faunce et al., Linkage pharmaceutical evergreening in Canada and Australia, June 2007

5 How to achieve the balance? Interpretation of treaties to give rights to right holders but also to prevent abuse of patent rights that leads to dangerous ever-greening practices that cost governments billions of dollars due to delays in introducing cost saving generics. (According to a 1998 study by the Congressional Budget office, generic drugs save consumers between $8-$10 billion each year). Enacting anti-ever-greening laws if need be (the Australian experience post AUS-USFTA). Analysts agree that the most dangerous type of ever-greening is linkage between marketing approval and patent protection. Unlike later signed FTAs which has this language Jordan FTA does not have such a linkage.

6 Interpretation of treaties under International Law : General Rules 1.Good faith and ordinary meaning of text (Plain meaning rule/civil and common law) within the treatys context. (Context includes preamble and annexes and agreement in conclusion of treaty or instrument accepted as part of treaty) 2.In addition to Context subsequent agreement regarding interpretation. Subsequent practice in application establishing agreement on interpretation. 3.A special meaning shall be given to a term if so intended.

7 Interpretation of Treaties: Supplementary Preparatory work and circumstances of conclusion should be consulted if the interpretation under the general rules: –Leaves the meaning ambiguous –Leads to a result which is manifestly absurd or unreasonable.

8 Example on Context: Data protection issues under the JORDAN-USFTA Article 4.22 Pursuant to Article 39.3 of TRIPS each Party, when requiring 1), as a condition of approving the marketing of pharmaceutical or of agricultural chemical products 2) that utilize new 3) chemical entities 4), the submission of undisclosed 5) test or other data, or evidence of approval in another country, the origination 6) of which involves a considerable effort 7), shall protect such information against unfair commercial use 8). In addition 9), Members shall protect such data against disclosure 10), except where necessary to protect the public, or unless steps are taken to ensure that the data are protected against unfair commercial use. 11)

9 Data Protection: Context The FTA accepts TRIPS Article 39.3 as the basis for the data exclusivity article. Therefore, any meaning given to the terms in this article that legal scholars or lawyers deem as consistent with the TRIPS agreement is consistent with the context of this agreement.

10 Example on Ordinary Meaning Jordan US FTA provisions related to pharmaceutical Products Article 4.23 (a) Each Party shall make available an extension of the patent term to compensate the patent owner for unreasonable curtailment of the patent term as a result of the marketing approval process. Make available: mechanism for inducing the applicant to ask for extension and cap on extension e.g. the US gives the patent holder 60 days post approval to inform the patent office, otherwise, the holder is not granted extension. The extension cannot exceed five years and the total term of a patent plus extension cannot exceed 14 years Unreasonable; what does unreasonable mean? There should be a timeline that takes into consideration many factors including the applicants diligence

11 Example 2 on Ordinary meaning; Hint at Linkage-Ever-greening? Article 4.23.(b) The patent owner shall be notified of the identity of any third party requesting marketing approval effective during the term of the patent. NO. Ordinary meaning rule requires only that patent owner be notified and it does not require the generic to notify.

12 Example on Subsequent Practice US practice post agreement is different than Jordan. Application of a generic is an act of infringement in the US but in Jordan it is not.

13 Example on Subsequent Practice Infringement of a patent under US patent law 35 USC 271: Infringement of a patent (e) (1) It shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products. (Regulatory Exception) (2) It shall be an act of infringement to submit - (A) an application under section 505(j) of the Federal Food, Drug, and Cosmetic Act or described in section 505(b)(2) of such Act for a drug claimed in a patent or the use of which is claimed in a patent…

14 Example on Subsequent Practice: Patent Holder Rights Under Jordanian Patent Law Article 21 C. Notwithstanding any conflicting provision in this law or any other law, all types of scientific research and development (Regulatory Exception) and filing applications for obtaining marketing permits carried out before the elapse of the patent protection period shall not be regarded as infringement neither civil nor criminal.

15 Access to medicines: A Stable Legal Environment The government should ensure: Transparency of laws and balance between rule and exception. Not assuming role of legislator by reading into the law what is not written. Not assuming a role reserved for courts by becoming the enforcer of private IP rights. Keeping a record of the negotiating history of any agreement that affects access to medicines. Learning the field. Making teams of international as well as national lawyers. Seeking lawyers to prevent problems as well as to solve them